Acadia Pharma (NASDAQ: ACAD) reported Q2 EPS of $0.01, $0.11 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $165.2 million versus the consensus estimate of $163.86 million.

GUIDANCE:

DAYBUE third quarter net sales in the range of $45 to $55 million.

Acadia Pharma sees FY2023 revenue of $530-545 million, versus the consensus of $652.1 million.

For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.